Assignee
ABLYNX NV
BE·127 granted patents·97 pending applications·563 citations·filing 2002–2025
Top patents by PatentIndex Score
224 records- 0199US11485777B2Immunoglobulin variable domainsABLYNX NV·Filed 2021·Granted Nov 1, 2022·8 cites·16 claims
- 0299US11485778B2Immunoglobulin variable domainsABLYNX NV·Filed 2021·Granted Nov 1, 2022·7 cites·10 claims
- 0399US11319364B2Immunoglobulin variable domainsABLYNX NV·Filed 2021·Granted May 3, 2022·8 cites·13 claims
- 0499US11312765B2Immunoglobulin variable domainsABLYNX NV·Filed 2021·Granted Apr 26, 2022·9 cites·15 claims
- 0599US11220539B2Immunoglobulin variable domainsABLYNX NV·Filed 2020·Granted Jan 11, 2022·9 cites·23 claims
- 0698US11708404B2Immunoglobulin variable domainsABLYNX NV·Filed 2022·Granted Jul 25, 2023·4 cites·14 claims
- 0797US11753465B2Nucleic acids encoding polypeptides against IL-23ABLYNX NV·Filed 2021·Granted Sep 12, 2023·3 cites·12 claims
- 0897US11312764B2Immunoglobulin variable domainsABLYNX NV·Filed 2019·Granted Apr 26, 2022·10 cites·19 claims
- 0997US10858418B2Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domainsABLYNX NV·Filed 2020·Granted Dec 8, 2020·18 cites·20 claims
- 1097US7807162B2Single domain VHH antibodies against von Willebrand factorABLYNX NV·Filed 2006·Granted Oct 5, 2010·72 cites·6 claims
- 1195US11142569B2Serum albumin-binding immunoglobulin variable domainsABLYNX NV·Filed 2016·Granted Oct 12, 2021·10 cites·11 claims
- 1295US10968271B2Polypeptides against IL-23ABLYNX NV·Filed 2016·Granted Apr 6, 2021·9 cites·8 claims
- 1395US9067991B2Nanobodies against tumor necrosis factor-alphaABLYNX NV·Filed 2014·Granted Jun 30, 2015·21 cites·19 claims
- 1494US11426468B2Cysteine linked nanobody dimersABLYNX NV·Filed 2015·Granted Aug 30, 2022·14 cites·6 claims
- 1594US11208476B2Polypeptides comprising immunoglobulin single variable domains targeting IL-13 and TSLPABLYNX NV·Filed 2021·Granted Dec 28, 2021·12 cites·12 claims
- 1694US9745372B2TNF bindersABLYNX NV·Filed 2017·Granted Aug 29, 2017·18 cites·2 claims
- 1793US11332519B2Serum albumin bindersABLYNX NV·Filed 2016·Granted May 17, 2022·7 cites·18 claims
- 1893US11009511B2Methods for detecting and/or measuring anti-drug antibodies, in particular treatment-emergent anti-drug antibodiesABLYNX NV·Filed 2015·Granted May 18, 2021·6 cites·7 claims
- 1993US10927186B2T cell recruiting polypeptides based on TCR alpha/beta reactivityABLYNX NV·Filed 2016·Granted Feb 23, 2021·19 cites·20 claims
- 2093US10844123B2Amino acid sequences that modulate the interaction between cells of the immune systemABLYNX NV·Filed 2018·Granted Nov 24, 2020·4 cites·25 claims
- 2193US10087251B2Amino acid sequences that modulate the interaction between cells of the immune systemABLYNX NV·Filed 2016·Granted Oct 2, 2018·9 cites·21 claims
- 2293US9683045B2Biological materials related to c-MetABLYNX NV·Filed 2014·Granted Jun 20, 2017·17 cites·12 claims
- 2393US9346884B2Biological materials related to c-MetABLYNX NV·Filed 2012·Granted May 24, 2016·15 cites·5 claims
- 2492US11332525B2Polypeptides comprising immunoglobulin single variable domains targeting TNFA and IL-23ABLYNX NV·Filed 2021·Granted May 17, 2022·4 cites·14 claims
- 2592US11192937B2Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domainsABLYNX NV·Filed 2017·Granted Dec 7, 2021·5 cites·6 claims
- 2692US11192938B2Serum albumin binding proteins containing immunoglobulin single variable domainsABLYNX NV·Filed 2017·Granted Dec 7, 2021·5 cites·35 claims
- 2792US10550174B2Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseasesABLYNX NV·Filed 2017·Granted Feb 4, 2020·6 cites·20 claims
- 2892US10544211B2TNF bindersABLYNX NV·Filed 2016·Granted Jan 28, 2020·14 cites·4 claims
- 2992US8962805B2Anti IL-6R polypeptides and compositions thereofABLYNX NV·Filed 2014·Granted Feb 24, 2015·14 cites·19 claims
- 3091US11414481B2Serum albumin bindersABLYNX NV·Filed 2018·Granted Aug 16, 2022·6 cites·22 claims
- 3191US9969805B2Amino acid sequences directed against HER2 and polypeptides comprising the same for the treatment of cancers and/or tumorsABLYNX NV·Filed 2015·Granted May 15, 2018·10 cites·20 claims
- 3291US9834595B2Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseasesABLYNX NV·Filed 2015·Granted Dec 5, 2017·6 cites·10 claims
- 3391US9273150B2Methods of using IL-6R antibodies to block or reduce binding of IL-6 to IL-6RABLYNX NV·Filed 2014·Granted Mar 1, 2016·11 cites·16 claims
- 3490US12516105B2Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domainsABLYNX NV·Filed 2021·Granted Jan 6, 2026·1 cites·9 claims
- 3590US9181350B2Nucleic acids encoding IL-6R-binding polypeptidesABLYNX NV·Filed 2014·Granted Nov 10, 2015·10 cites·23 claims
- 3690US8372398B2Single domain VHH antibodies against Von Willebrand FactorABLYNX NV·Filed 2010·Granted Feb 12, 2013·14 cites·12 claims
- 3789US11897951B2Polypeptides comprising immunoglobulin single variable domains targeting IL-6 and TNF-αABLYNX NV·Filed 2021·Granted Feb 13, 2024·3 cites·18 claims
- 3889US10208115B2Amino acid sequences that modulate the interaction between cells of the immune systemABLYNX NV·Filed 2016·Granted Feb 19, 2019·5 cites·25 claims
- 3989US9605072B2Nucleic acids that encode interleukin-6 receptor binding polypeptidesABLYNX NV·Filed 2014·Granted Mar 28, 2017·8 cites·42 claims
- 4089US9265834B2Stable formulations of polypeptides and uses thereofABLYNX NV·Filed 2013·Granted Feb 23, 2016·8 cites·25 claims
- 4189US2024182575A1Amino acid sequences that modulate the interaction between cells of the immune systemABLYNX NV·Filed 2023·Application pending·0 cites
- 4288US12180268B2Immunoglobulin variable domainsABLYNX NV·Filed 2015·Granted Dec 31, 2024·2 cites·10 claims
- 4388US11840566B2Methods of treating asthma with polypeptides targeting IL-13 and TSLPABLYNX NV·Filed 2021·Granted Dec 12, 2023·1 cites·18 claims
- 4488US11384151B2CX3CR1-binding polypeptides comprising immunoglobulin single variable domainsABLYNX NV·Filed 2019·Granted Jul 12, 2022·2 cites·11 claims
- 4588US9611326B2Interleukin-6 receptor binding polypeptidesABLYNX NV·Filed 2013·Granted Apr 4, 2017·7 cites·22 claims
- 4687US12553901B2Methods for detecting and/or measuring anti-drug antibodies, in particular treatment-emergent anti-drug antibodiesABLYNX NV·Filed 2021·Granted Feb 17, 2026·1 cites·10 claims
- 4787US11932702B2Polypeptides comprising immunoglobulin single variable domains targeting glypican-3 and T cell receptorABLYNX NV·Filed 2021·Granted Mar 19, 2024·3 cites·28 claims
- 4887US11046767B2T cell recruiting polypeptides based on CD3 reactivityABLYNX NV·Filed 2016·Granted Jun 29, 2021·5 cites·17 claims
- 4987US9617341B2Methods for blocking or reducing binding of interleukin-6 to interleukin-6 receptorABLYNX NV·Filed 2014·Granted Apr 11, 2017·7 cites·34 claims
- 5087US9371381B2Single domain antibodies directed against tumor necrosis factor-alpha and uses thereforABLYNX NV·Filed 2014·Granted Jun 21, 2016·5 cites·16 claims
Showing the top 50 of 224 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when ABLYNX NV files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →